Rare Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

North America Leads with a Dominant Market Share

The global rare disease treatment market is on an upward trajectory, with the genetic diseases segment expected to maintain its dominance in the coming years, according to a comprehensive research report. Nearly 80 percent of rare diseases have a genetic origin, making this segment a significant player in the market. The report forecasts the genetic diseases segment to reach a substantial market valuation of US$ 56 billion by 2024.

Following closely behind the genetic diseases segment, the oncology sector is expected to be the second-largest segment in terms of market share, albeit with a lower growth rate compared to genetic diseases. Meanwhile, the metabolic diseases segment is poised for the highest growth rate during the forecast period from 2024 to 2031, closely followed by the neurological diseases segment.

North America Leading the Charge

North America is projected to retain its position as the largest regional market for rare disease treatment from 2024 to 2031. The genetic diseases segment is anticipated to drive significant growth in this region, with a robust Compound Annual Growth Rate (CAGR) forecasted.

The metabolic diseases testing segment within North America is also expected to exhibit substantial growth potential, thanks to a well-established healthcare system and various reimbursement policies aimed at facilitating treatments for rare disease patients. The genetic diseases treatment segment in the North American regional market is poised to be especially lucrative during the forecast period, with an attractive market share index of 4.2.

Factors Driving Growth

The global rare disease treatment market's positive trajectory is influenced by several factors, both direct and indirect. According to the research report, the market is projected to reach a valuation of US$ 198,487 million in 2024.

Push factors contributing to market growth include increasing government support, incentives provided to pharmaceutical companies, heightened public awareness and advocacy efforts, improved communication among healthcare professionals to discover efficient treatment methods, enhanced patient facilities, and increased research incentives supported by non-profit organizations focused on rare diseases. Furthermore, government regulations, including reduced taxes on expensive medicines and higher research funding, along with favorable regulatory assistance, are bolstering market growth.

However, challenges in research and development, delays in diagnosis, limitations in expertise, a lack of economic attractiveness, and limited commercial interest from private investors are factors that restrain market growth, particularly in developing economies with inadequate regulatory frameworks and a shortage of skilled healthcare personnel.

Competitive Analysis

Key players in the Rare Disease Treatment Market including-

Novartis AG
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Celgene Corporation
AbbVie Inc.
Johnson & Johnson Services, Inc.
Shire
Alexion
Novo Nordisk A/S
Sanofi
Bayer AG
Amgen, Inc.
Allergan plc.
Eisai Co. Ltd.
Bristol-Myers Squibb Company
Merck & Co., Inc.
Vertex Pharmaceuticals
Baxter
BioMarin
Teva Pharmaceutical Industries Ltd.
Others

Market Segmentation

By Therapeutic Area

Hematology
Genetic Diseases
Neurological Diseases
Oncology
Infectious Diseases
Inflammatory Diseases
Metabolic Diseases
Pulmonary Diseases
Kidney Diseases
Musculoskeletal Diseases
Endocrine Diseases
Skin Disorders

By Drug Type

Originator Drugs (Patented Molecules)
Generic Drugs

By Drug Class

Biologics
Organic Compounds

By Mode of Administration

Injectable
Oral
Others (includes topical preparations)

By Distribution Channel

Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies

By Region

North America
Latin America
Europe
Asia Pacific (APAC)
Middle East and Africa (MEA)

1. Executive Summary

1.1. Global Rare Disease Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Rare Disease Treatment Market Outlook, 2018 - 2031

3.1. Global Rare Disease Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Originator Drugs (Patented Molecules)
  - 3.1.1.2. Generic Drugs
3.2. Global Rare Disease Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Biologics
  - 3.2.1.2. Organic Compounds
3.3. Global Rare Disease Treatment Market Outlook, by Therapeutic Area, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Hematology
  - 3.3.1.2. Genetic Diseases
  - 3.3.1.3. Neurological Diseases
  - 3.3.1.4. Oncology
  - 3.3.1.5. Infectious Diseases
  - 3.3.1.6. Inflammatory Diseases
  - 3.3.1.7. Metabolic Diseases
  - 3.3.1.8. Pulmonary Diseases
  - 3.3.1.9. Kidney Diseases
  - 3.3.1.10. Musculoskeletal Diseases
  - 3.3.1.11. Endocrine Diseases
  - 3.3.1.12. Skin Disorders
3.4. Global Rare Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. Injectable
  - 3.4.1.2. Oral
  - 3.4.1.3. Others (includes topical preparations)
3.5. Global Rare Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.5.1. Key Highlights
  - 3.5.1.1. Hospital Pharmacies
  - 3.5.1.2. Specialty Pharmacies
  - 3.5.1.3. Retail Pharmacies
3.6. Global Rare Disease Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.6.1. Key Highlights
  - 3.6.1.1. North America
  - 3.6.1.2. Europe
  - 3.6.1.3. Asia Pacific
  - 3.6.1.4. Latin America
  - 3.6.1.5. Middle East & Africa

4. North America Rare Disease Treatment Market Outlook, 2018 - 2031

4.1. North America Rare Disease Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Originator Drugs (Patented Molecules)
  - 4.1.1.2. Generic Drugs
4.2. North America Rare Disease Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Biologics
  - 4.2.1.2. Organic Compounds
4.3. North America Rare Disease Treatment Market Outlook, by Therapeutic Area, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Hematology
  - 4.3.1.2. Genetic Diseases
  - 4.3.1.3. Neurological Diseases
  - 4.3.1.4. Oncology
  - 4.3.1.5. Infectious Diseases
  - 4.3.1.6. Inflammatory Diseases
  - 4.3.1.7. Metabolic Diseases
  - 4.3.1.8. Pulmonary Diseases
  - 4.3.1.9. Kidney Diseases
  - 4.3.1.10. Musculoskeletal Diseases
  - 4.3.1.11. Endocrine Diseases
  - 4.3.1.12. Skin Disorders
4.4. North America Rare Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. Injectable
  - 4.4.1.2. Oral
  - 4.4.1.3. Others (includes topical preparations)
4.5. North America Rare Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.5.1. Key Highlights
  - 4.5.1.1. Hospital Pharmacies
  - 4.5.1.2. Specialty Pharmacies
  - 4.5.1.3. Retail Pharmacies
4.6. North America Rare Disease Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.6.1. Key Highlights
  - 4.6.1.1. U.S. Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 4.6.1.2. U.S. Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.6.1.3. U.S. Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 4.6.1.4. U.S. Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 4.6.1.5. U.S. Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.6.1.6. Canada Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 4.6.1.7. Canada Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.6.1.8. Canada Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 4.6.1.9. Canada Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 4.6.1.10. Canada Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.6.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Rare Disease Treatment Market Outlook, 2018 - 2031

5.1. Europe Rare Disease Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Originator Drugs (Patented Molecules)
  - 5.1.1.2. Generic Drugs
5.2. Europe Rare Disease Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Biologics
  - 5.2.1.2. Organic Compounds
5.3. Europe Rare Disease Treatment Market Outlook, by Therapeutic Area, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Hematology
  - 5.3.1.2. Genetic Diseases
  - 5.3.1.3. Neurological Diseases
  - 5.3.1.4. Oncology
  - 5.3.1.5. Infectious Diseases
  - 5.3.1.6. Inflammatory Diseases
  - 5.3.1.7. Metabolic Diseases
  - 5.3.1.8. Pulmonary Diseases
  - 5.3.1.9. Kidney Diseases
  - 5.3.1.10. Musculoskeletal Diseases
  - 5.3.1.11. Endocrine Diseases
  - 5.3.1.12. Skin Disorders
5.4. Europe Rare Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Injectable
  - 5.4.1.2. Oral
  - 5.4.1.3. Others (includes topical preparations)
5.5. Europe Rare Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.5.1. Key Highlights
  - 5.5.1.1. Hospital Pharmacies
  - 5.5.1.2. Specialty Pharmacies
  - 5.5.1.3. Retail Pharmacies
5.6. Europe Rare Disease Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.6.1. Key Highlights
  - 5.6.1.1. Germany Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.6.1.2. Germany Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.3. Germany Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.6.1.4. Germany Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 5.6.1.5. Germany Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.6.1.6. U.K. Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.6.1.7. U.K. Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.8. U.K. Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.6.1.9. U.K. Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 5.6.1.10. U.K. Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.6.1.11. France Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.6.1.12. France Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.13. France Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.6.1.14. France Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 5.6.1.15. France Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.6.1.16. Italy Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.6.1.17. Italy Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.18. Italy Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.6.1.19. Italy Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 5.6.1.20. Italy Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.6.1.21. Turkey Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.6.1.22. Turkey Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.23. Turkey Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.6.1.24. Turkey Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 5.6.1.25. Turkey Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.6.1.26. Russia Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.6.1.27. Russia Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.28. Russia Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.6.1.29. Russia Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 5.6.1.30. Russia Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.6.1.31. Rest of Europe Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.6.1.32. Rest of Europe Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.33. Rest of Europe Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.6.1.34. Rest of Europe Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 5.6.1.35. Rest of Europe Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.6.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Rare Disease Treatment Market Outlook, 2018 - 2031

6.1. Asia Pacific Rare Disease Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Originator Drugs (Patented Molecules)
  - 6.1.1.2. Generic Drugs
6.2. Asia Pacific Rare Disease Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Biologics
  - 6.2.1.2. Organic Compounds
6.3. Asia Pacific Rare Disease Treatment Market Outlook, by Therapeutic Area, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Hematology
  - 6.3.1.2. Genetic Diseases
  - 6.3.1.3. Neurological Diseases
  - 6.3.1.4. Oncology
  - 6.3.1.5. Infectious Diseases
  - 6.3.1.6. Inflammatory Diseases
  - 6.3.1.7. Metabolic Diseases
  - 6.3.1.8. Pulmonary Diseases
  - 6.3.1.9. Kidney Diseases
  - 6.3.1.10. Musculoskeletal Diseases
  - 6.3.1.11. Endocrine Diseases
  - 6.3.1.12. Skin Disorders
6.4. Asia Pacific Rare Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Injectable
  - 6.4.1.2. Oral
  - 6.4.1.3. Others (includes topical preparations)
6.5. Asia Pacific Rare Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.5.1. Key Highlights
  - 6.5.1.1. Hospital Pharmacies
  - 6.5.1.2. Specialty Pharmacies
  - 6.5.1.3. Retail Pharmacies
6.6. Asia Pacific Rare Disease Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.6.1. Key Highlights
  - 6.6.1.1. China Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 6.6.1.2. China Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.6.1.3. China Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 6.6.1.4. China Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 6.6.1.5. China Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.6.1.6. Japan Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 6.6.1.7. Japan Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.6.1.8. Japan Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 6.6.1.9. Japan Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 6.6.1.10. Japan Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.6.1.11. South Korea Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 6.6.1.12. South Korea Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.6.1.13. South Korea Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 6.6.1.14. South Korea Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 6.6.1.15. South Korea Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.6.1.16. India Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 6.6.1.17. India Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.6.1.18. India Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 6.6.1.19. India Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 6.6.1.20. India Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.6.1.21. Southeast Asia Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 6.6.1.22. Southeast Asia Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.6.1.23. Southeast Asia Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 6.6.1.24. Southeast Asia Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 6.6.1.25. Southeast Asia Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.6.1.26. Rest of Asia Pacific Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 6.6.1.27. Rest of Asia Pacific Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.6.1.28. Rest of Asia Pacific Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 6.6.1.29. Rest of Asia Pacific Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 6.6.1.30. Rest of Asia Pacific Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.6.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Rare Disease Treatment Market Outlook, 2018 - 2031

7.1. Latin America Rare Disease Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Originator Drugs (Patented Molecules)
  - 7.1.1.2. Generic Drugs
7.2. Latin America Rare Disease Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Biologics
  - 7.2.1.2. Organic Compounds
7.3. Latin America Rare Disease Treatment Market Outlook, by Therapeutic Area, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Hematology
  - 7.3.1.2. Genetic Diseases
  - 7.3.1.3. Neurological Diseases
  - 7.3.1.4. Oncology
  - 7.3.1.5. Infectious Diseases
  - 7.3.1.6. Inflammatory Diseases
  - 7.3.1.7. Metabolic Diseases
  - 7.3.1.8. Pulmonary Diseases
  - 7.3.1.9. Kidney Diseases
  - 7.3.1.10. Musculoskeletal Diseases
  - 7.3.1.11. Endocrine Diseases
  - 7.3.1.12. Skin Disorders
7.4. Latin America Rare Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Injectable
  - 7.4.1.2. Oral
  - 7.4.1.3. Others (includes topical preparations)
7.5. Latin America Rare Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Hospital Pharmacies
  - 7.5.1.2. Specialty Pharmacies
  - 7.5.1.3. Retail Pharmacies
7.6. Latin America Rare Disease Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.6.1. Key Highlights
  - 7.6.1.1. Brazil Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 7.6.1.2. Brazil Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.6.1.3. Brazil Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 7.6.1.4. Brazil Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 7.6.1.5. Brazil Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.6.1.6. Mexico Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 7.6.1.7. Mexico Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.6.1.8. Mexico Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 7.6.1.9. Mexico Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 7.6.1.10. Mexico Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.6.1.11. Argentina Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 7.6.1.12. Argentina Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.6.1.13. Argentina Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 7.6.1.14. Argentina Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 7.6.1.15. Argentina Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.6.1.16. Rest of Latin America Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 7.6.1.17. Rest of Latin America Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.6.1.18. Rest of Latin America Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 7.6.1.19. Rest of Latin America Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 7.6.1.20. Rest of Latin America Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Rare Disease Treatment Market Outlook, 2018 - 2031

8.1. Middle East & Africa Rare Disease Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Originator Drugs (Patented Molecules)
  - 8.1.1.2. Generic Drugs
8.2. Middle East & Africa Rare Disease Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Biologics
  - 8.2.1.2. Organic Compounds
8.3. Middle East & Africa Rare Disease Treatment Market Outlook, by Therapeutic Area, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Hematology
  - 8.3.1.2. Genetic Diseases
  - 8.3.1.3. Neurological Diseases
  - 8.3.1.4. Oncology
  - 8.3.1.5. Infectious Diseases
  - 8.3.1.6. Inflammatory Diseases
  - 8.3.1.7. Metabolic Diseases
  - 8.3.1.8. Pulmonary Diseases
  - 8.3.1.9. Kidney Diseases
  - 8.3.1.10. Musculoskeletal Diseases
  - 8.3.1.11. Endocrine Diseases
  - 8.3.1.12. Skin Disorders
8.4. Middle East & Africa Rare Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Injectable
  - 8.4.1.2. Oral
  - 8.4.1.3. Others (includes topical preparations)
8.5. Middle East & Africa Rare Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.5.1. Key Highlights
  - 8.5.1.1. Hospital Pharmacies
  - 8.5.1.2. Specialty Pharmacies
  - 8.5.1.3. Retail Pharmacies
8.6. Middle East & Africa Rare Disease Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.6.1. Key Highlights
  - 8.6.1.1. GCC Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 8.6.1.2. GCC Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.6.1.3. GCC Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 8.6.1.4. GCC Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 8.6.1.5. GCC Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.6.1.6. South Africa Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 8.6.1.7. South Africa Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.6.1.8. South Africa Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 8.6.1.9. South Africa Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 8.6.1.10. South Africa Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.6.1.11. Egypt Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 8.6.1.12. Egypt Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.6.1.13. Egypt Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 8.6.1.14. Egypt Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 8.6.1.15. Egypt Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.6.1.16. Nigeria Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 8.6.1.17. Nigeria Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.6.1.18. Nigeria Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 8.6.1.19. Nigeria Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 8.6.1.20. Nigeria Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.6.1.21. Rest of Middle East & Africa Rare Disease Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 8.6.1.22. Rest of Middle East & Africa Rare Disease Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.6.1.23. Rest of Middle East & Africa Rare Disease Treatment Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 8.6.1.24. Rest of Middle East & Africa Rare Disease Treatment Market by Mode of Administration, Value (US$ Bn), 2018 - 2031
  - 8.6.1.25. Rest of Middle East & Africa Rare Disease Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.6.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Therapeutic Area vs By Drug Class Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Novartis AG
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Pfizer Inc.
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. F. Hoffmann-La Roche Ltd.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Celgene Corporation
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. AbbVie Inc.
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Johnson & Johnson Services, Inc.
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Shire
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Alexion
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Novo Nordisk A/S
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Sanofi
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. Bayer AG
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development
- 9.4.12. Amgen, Inc.
  - 9.4.12.1. Company Overview
  - 9.4.12.2. Product Portfolio
  - 9.4.12.3. Financial Overview
  - 9.4.12.4. Business Strategies and Development
- 9.4.13. Allergan plc.
  - 9.4.13.1. Company Overview
  - 9.4.13.2. Product Portfolio
  - 9.4.13.3. Financial Overview
  - 9.4.13.4. Business Strategies and Development
- 9.4.14. Eisai Co. Ltd.
  - 9.4.14.1. Company Overview
  - 9.4.14.2. Product Portfolio
  - 9.4.14.3. Financial Overview
  - 9.4.14.4. Business Strategies and Development
- 9.4.15. Bristol-Myers Squibb Company
  - 9.4.15.1. Company Overview
  - 9.4.15.2. Product Portfolio
  - 9.4.15.3. Financial Overview
  - 9.4.15.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations